SV2 is the protein receptor for botulinum neurotoxin A M Dong, F Yeh, WH Tepp, C Dean, EA Johnson, R Janz, ER Chapman Science 312 (5773), 592-596, 2006 | 948 | 2006 |
TREM2 binds to apolipoproteins, including APOE and CLU/APOJ, and thereby facilitates uptake of amyloid-beta by microglia FL Yeh, Y Wang, I Tom, LC Gonzalez, M Sheng Neuron 91 (2), 328-340, 2016 | 878 | 2016 |
TREM2, microglia, and neurodegenerative diseases FL Yeh, DV Hansen, M Sheng Trends in molecular medicine 23 (6), 512-533, 2017 | 411 | 2017 |
SV2 mediates entry of tetanus neurotoxin into central neurons FL Yeh, M Dong, J Yao, WH Tepp, G Lin, EA Johnson, ER Chapman PLoS pathogens 6 (11), e1001207, 2010 | 162 | 2010 |
Biophysical characterization of styryl dye-membrane interactions Y Wu, FL Yeh, F Mao, ER Chapman Biophysical journal 97 (1), 101-109, 2009 | 87 | 2009 |
Interneuronal transfer and distal action of tetanus toxin and botulinum neurotoxins A and D in central neurons E Bomba-Warczak, JD Vevea, JM Brittain, A Figueroa-Bernier, WH Tepp, ... Cell reports 16 (7), 1974-1987, 2016 | 78 | 2016 |
All three components of the neuronal SNARE complex contribute to secretory vesicle docking Y Wu, Y Gu, MK Morphew, J Yao, FL Yeh, M Dong, ER Chapman Journal of Cell Biology 198 (3), 323-330, 2012 | 35 | 2012 |
A Phase 1 study of GDC‐0134, a dual leucine zipper kinase inhibitor, in ALS JS Katz, JD Rothstein, ME Cudkowicz, A Genge, B Oskarsson, AB Hains, ... Annals of clinical and translational neurology 9 (1), 50-66, 2022 | 30 | 2022 |
Latozinemab, a novel progranulin-elevating therapy for frontotemporal dementia M Kurnellas, A Mitra, T Schwabe, R Paul, AE Arrant, ED Roberson, ... Journal of Translational Medicine 21 (1), 387, 2023 | 19 | 2023 |
Retargeted clostridial neurotoxins as novel agents for treating chronic diseases FL Yeh, Y Zhu, WH Tepp, EA Johnson, PJ Bertics, ER Chapman Biochemistry 50 (48), 10419-10421, 2011 | 17 | 2011 |
A phase 1 study of AL002 in healthy volunteers M Ward, H Long, T Schwabe, H Rhinn, I Tassi, SV Salazar, A Rychkova, ... Alzheimer's & Dementia 17, e054669, 2021 | 10 | 2021 |
Multiple doses of an anti-FGFR1/KLB bispecific antibody (BFKB8488A) are associated with a decrease in hepatic fat in patients with NAFLD R Kunder, F Yeh, LW Chinn, A Dash, N Lewin-Koh, N Kim, J Fredrickson, ... Hepatology 70 (6), 1493A-1493A, 2019 | 8 | 2019 |
Btbd11 is an inhibitory interneuron specific synaptic scaffolding protein that supports excitatory synapse structure and function AM Bygrave, A Sengupta, EP Jackert, M Ahmed, B Adenuga, E Nelson, ... Biorxiv, 2021.11. 01.466782, 2021 | 7 | 2021 |
INVOKE‐2: A phase 2 randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of AL002 in participants with early Alzheimer’s disease R Paul, S Jackson, M Ward, A Joshi, A Castro, FL Yeh, Y Liao, G Morrison Alzheimer's & Dementia 17, e054615, 2021 | 5 | 2021 |
A BISPECIFIC ANTIBODY TO FGFR1/KLB, BFKB8488A, IMPROVES LIPID PROFILE, MARKERS OF FIBROGENESIS AND LIVER HEALTH IN PATIENTS WITH TYPE 2 DIABETES-PRELIMINARY RESULTS FROM A … C Wong, F Yeh, L Chinn, A Dash, N Lewin-Koh, K Yoshida, S Chen, ... HEPATOLOGY 70, 1358A-1359A, 2019 | 5 | 2019 |
Btbd11 supports cell-type-specific synaptic function AM Bygrave, A Sengupta, EP Jackert, M Ahmed, B Adenuga, E Nelson, ... Cell reports 42 (6), 2023 | 4 | 2023 |
Preclinical and first-in-human evaluation of AL002, a novel TREM2 agonistic antibody for Alzheimer’s disease H Long, A Simmons, A Mayorga, B Burgess, T Nguyen, B Budda, ... Alzheimer's Research & Therapy 16 (1), 235, 2024 | 3 | 2024 |
A Phase 1 Study of AL003 in Healthy Volunteers and Participants with Alzheimer’s disease (P5-3.002) D Maslyar, R Paul, H Long, H Rhinn, I Tassi, G Morrison, F Yeh, ... Neurology 98 (18_supplement), 3582, 2022 | 3 | 2022 |
AL001 restores CSF PGRN levels and normalizes disease‐associated biomarkers in individuals with frontotemporal dementia due to heterozygous mutations in the progranulin gene … BA Haynes, H Rhinn, FL Yeh, H Long, M Ward, M Hagey, O Siddiqui, ... Alzheimer's & Dementia 16, e046114, 2020 | 3 | 2020 |
A Phase 1 Study of AL002 in Healthy Volunteers (P5-3.004) M Ward, R Paul, H Long, H Rhinn, A Rychkova, G Tu, C Barner, S Salazar, ... Neurology 98 (18_supplement), 3133, 2022 | 2 | 2022 |